



Hepatitis B Virus Immunity Status and Booster Dose Efficacy in Health Sciences Students: An Interventional Study

Seyyed Javad Hosseini Shokouh^{1,2,*}, Iman Naseh¹, Mohamad Barati¹, Mohammad Gholami¹, Alireza Farkhonderay¹

¹ Infectious Diseases Research Center, Aja University of Medical Sciences, Tehran, Iran

² Iranian Research Center for HIV/AIDS (IRCHA), Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran

*Corresponding Author: Infectious Diseases Research Center, Aja University of Medical Sciences, Tehran, Iran. Email: sjavadhsh@yahoo.com

Received: 7 August, 2024; Revised: 25 October, 2024; Accepted: 2 November, 2024

Abstract

Background: Hepatitis B virus (HBV) infection poses a significant health risk for healthcare workers (HCWs) and students due to occupational exposure to blood and body fluids.

Objectives: This study investigated the immunity status of health sciences students and evaluated the efficacy of a booster dose for individuals with insufficient Hepatitis B surface antibody (anti-HBs) titers (<10 mIU/mL).

Methods: This interventional study was conducted at Aja University of Medical Sciences between January 2023 and January 2024. A total of 356 health sciences students from various fields participated in the study. Hepatitis B surface antibody levels were measured initially, and individuals with insufficient titers received a booster dose. Hepatitis B surface antibody levels were re-evaluated four weeks after the booster dose. Participants were categorized based on their anti-HBs levels, and chi-square and *t*-tests were used for statistical comparisons.

Results: Nearly all participants had received the hepatitis B vaccine during infancy. Among the total participants, 249 individuals (69.9%) demonstrated sufficient antibody levels (≥ 10 mIU/mL), while 107 participants (30.1%) had insufficient levels (<10 mIU/mL). Of the 107 participants with inadequate antibody levels, 96 returned for follow-up testing after the booster dose. Among these, 93 individuals (96.9%) achieved sufficient antibody levels (≥ 10 mIU/mL), while three participants (3.1%) continued to show insufficient levels (<10 mIU/mL).

Conclusions: A considerable proportion of health sciences students in this study exhibited insufficient anti-HBs titers (<10 mIU/mL). The administration of a booster dose effectively restored sufficient antibody levels in 96.9% of the affected participants. Greater emphasis should be placed on monitoring and maintaining the hepatitis B immunity status of health sciences students. Further research is needed to understand immunity dynamics and the impact of booster doses in high-risk populations.

Keywords: Hepatitis B, Hepatitis B Antibodies, Hepatitis B Vaccine, Revaccination, Booster Immunization

1. Background

The hepatitis B virus (HBV) infection poses a significant health risk for healthcare workers (HCWs) due to occupational exposure to blood and body fluids (1, 2). Blood-borne HBV infections affect approximately 5.9% of HCWs annually, amounting to 66,000 infections worldwide (2). Infected HCWs may also transmit HBV to patients during surgery or exposure-prone procedures (3). For example, over eight years, a surgeon infected with HBV transmitted the virus to more than 100

individuals (4). Vaccination can prevent HBV transmission from patients to HCWs. However, not all HCWs are vaccinated or respond to vaccination as expected (4). Furthermore, even after successful vaccination, antibody levels may decrease over time (5).

Despite the high efficacy of the hepatitis B vaccine, uncertainties remain regarding the duration of its protection and the potential need for booster doses (6). Several studies have investigated the long-term effects of HBV vaccination, but the findings are inconsistent. Some studies affirm the long-term immunogenicity of

the hepatitis B vaccine and conclude that booster doses are unnecessary (7-9). Conversely, other studies report that antibody levels decline over time following vaccination, suggesting a booster dose may be required (10, 11). For instance, a survey of 243 participants revealed that 90% retained evidence of protection 30 years after hepatitis B vaccination (9). However, another study found that after 15 years, only one-third of the population maintained protective antibody levels (10).

2. Objectives

In addition to these controversies, there is a paucity of research on the HBV immune status of health sciences students and the efficacy of booster doses in Iran. This study aimed to evaluate the immunization status and Hepatitis B surface antibody (anti-HBs) titers of a group of health sciences students. Furthermore, it investigated the effect of a booster dose on participants with initially low antibody levels.

3. Methods

3.1. Study Design and Population

Based on a prior study (12), the power and sample size were calculated using the appropriate sample size formula (13) with $\alpha = 0.05$ and $\beta = 0.2$. This interventional study recruited participants from Aja University of Medical Sciences between January 2023 and January 2024. Participants included students from various disciplines, such as medicine, nursing, paramedicine, and dentistry. Paramedical students specialized in fields including anesthesiology, radiology, health information technology, laboratory medicine, and surgical technology. Baseline characteristics and information were collected for all participants, followed by the determination of their anti-HBs antibody levels.

Participants with insufficient antibody levels [< 10 milli-international units per milliliter (mIU/mL)] received a single dose of the hepatitis B vaccine. One month after the booster dose, the anti-HBs antibody levels were reassessed. No specific exclusion criteria were applied, ensuring a diverse representation of students across different disciplines and entry years. The procedures and purpose of the study were thoroughly explained to all participants before the study commenced, and informed consent was obtained prior to enrollment.

This study adhered to the principles of the Declaration of Helsinki. Ethical approval was granted by the Research Ethics Committee of Aja University of

Medical Sciences (Approval number: IR.AJAUMS.REC.1401.156).

3.2. Data Collection

A structured questionnaire was used to collect data, including age, gender, field of study, entry year, history of any disease, and current medication use. Information about HBV vaccination in infancy, the number of HBV vaccine doses received in infancy, adherence to the correct immunization schedule, and a history of needlestick injuries was also gathered. Participants could respond to these items with "Yes," "No," or "I don't know." The correct immunization schedule was defined as three doses administered over a period of 0, 1, and 6 months, based on the recommendations of the Centers for Disease Control and Prevention (CDC) (14).

A team of trained examiners measured the participants' anthropometric characteristics, including height and weight. Weight was measured using a Calibrated Balance Beam Scale, with values rounded to the nearest 0.1 kg, while a portable stadiometer was used to measure standing height, rounded to the nearest 0.1 cm. Body Mass Index (BMI) was calculated by dividing weight (kg) by height squared (m^2). Body Mass Index was categorized into three groups: Underweight ($BMI < 18.5 \text{ kg/m}^2$), normal weight ($18.5 \text{ kg/m}^2 \leq BMI < 25 \text{ kg/m}^2$), and overweight/obese ($BMI \geq 25 \text{ kg/m}^2$) (15).

3.3. Laboratory Evaluation

A blood sample (approximately 5 mL) was collected from each participant. Hepatitis B surface antigen (HBsAg) was detected in the serum samples using an enzyme-linked immunosorbent assay (ELISA). The assay utilized antibodies targeting HBsAg to bind specifically to the antigen, and positive results indicated the presence of the viral antigen in the sample. Hepatitis B surface antibodies were also measured using ELISA (Pishtazteb, Tehran, Iran). Serum samples were added to microtiter plates pre-coated with HBsAg. Following incubation and washing steps, an enzyme-linked anti-human IgG antibody was added. The subsequent color change was measured spectrophotometrically to determine the concentration of anti-HBs antibodies in the samples. Strict quality control measures were implemented throughout the process to ensure the reliability and accuracy of the results.

3.4. Vaccination

Participants with anti-HBs antibody levels < 10 mIU/mL received a booster dose of the recombinant hepatitis B vaccine (Pasteur Institute of Iran, Tehran,




Figure 1. Flow diagram of the study population; Insufficient Hepatitis B surface antibody (Anti-HBs): < 10 mIU/mL; Sufficient Anti-HBs: ≥ 10 mIU/mL.

Iran). A 1 mL dose of the vaccine, containing 20 μ g of recombinant HBsAg, was administered intramuscularly (IM) into the deltoid muscle of each participant. The research team advised participants to promptly report any unexpected symptoms or refer to a healthcare center following vaccination. Hepatitis B surface antibody levels were re-evaluated four weeks post-vaccination using ELISA, as previously described. A flow diagram outlining participant enrollment, intervention, and follow-up is provided in Figure 1.

3.5. Statistical Analysis

Data were analyzed using SPSS version 24 (IBM Corporation, New York, USA), and figures were created using GraphPad Prism version 9.4 (GraphPad Software, San Diego, CA, USA). The Kolmogorov-Smirnov test was employed to assess the normality of data distribution. Continuous variables were presented as means (\pm standard deviation), while categorical variables were expressed as frequencies and proportions. The chi-square test was used to compare categorical variables, and the *t*-test was applied to compare the means between groups.

Initially, participants were divided into two groups based on their anti-HBs levels: Insufficient anti-HBs (< 10 mIU/mL) and sufficient anti-HBs (≥ 10 mIU/mL). These

groups were compared for baseline characteristics. Subsequently, the group with sufficient anti-HBs levels was further classified into two subgroups ($10 \text{ mIU/mL} < \text{anti-HBs} < 100 \text{ mIU/mL}$ and $100 \text{ mIU/mL} \leq \text{anti-HBs}$), and comparisons were made between these subgroups. The same analysis was repeated for participants following vaccination. Statistical significance was set at a P-value < 0.05.

4. Results

4.1. Baseline Characteristics

A total of 356 individuals participated in this study, comprising 289 males (81.2%) and 67 females (18.8%). All participants tested negative for HBsAg. None of the participants had previously checked their anti-HBs levels before this study. Approximately 97.2% of the participants reported receiving the HBV vaccine during infancy. Additionally, 7.3% (26 individuals) reported experiencing needle stick injuries in the past. Table 1 summarizes the baseline characteristics of the participants, presented both overall and stratified by their immunity status.

Upon assessing anti-HBs antibody levels, 249 participants (69.9%) demonstrated sufficient antibody

Table 1. Comparison of Baseline Features According to Hepatitis B Surface Antibody Levels ^a

Variables	Total (N = 356)	Insufficient Anti-HBs Levels (N = 107) ^b	Sufficient Anti-HBs Levels; (N = 249) ^c
Age (y)	21.5 ± 1.8	21.2 ± 1.6	21.6 ± 1.8
Gender			
Male	289 (81.2)	86 (80.4)	203 (81.5)
Female	67 (18.8)	21 (19.6)	46 (18.5)
Field of study			
Medicine	164 (46.1)	50 (46.7)	114 (45.8)
Nursing	112 (31.5)	32 (29.9)	80 (32.1)
Para medicine	65 (18.3)	20 (18.7)	45 (18.1)
Dentistry	15 (4.2)	5 (4.7)	10 (4.0)
Year of study			
First	133 (37.4)	42 (39.2)	91 (36.5)
Second	103 (28.9)	27 (25.2)	76 (30.5)
Third	69 (19.4)	21 (19.6)	48 (19.3)
Fourth and above	51 (14.3)	17 (15.9)	34 (13.6)
Weight (kg)	73.1 ± 13.3	73.1 ± 14.0	73.0 ± 13.0
Height (cm)	176.2 ± 9.4	176.0 ± 9.8	176.3 ± 9.2
BMI (kg/m²)	23.4 ± 3.3	23.5 ± 3.3	23.4 ± 3.3
BMI category			
Underweight	16 (4.5)	6 (5.6)	10 (4.0)
Normal	241 (67.7)	71 (66.4)	170 (68.3)
Overweight and obese	99 (27.8)	30 (28.0)	69 (27.7)
Infancy vaccination			
Yes	346 (97.2)	106 (99.1)	240 (96.4)
No	0 (0)	0 (0)	0 (0)
Don't Know	10 (2.8)	1 (0.9)	9 (3.6)
Number of doses in infancy			
One	8 (2.2)	2 (1.9)	6 (2.4)
Two	37 (10.4)	9 (8.4)	28 (11.2)
Three	243 (68.3)	77 (72.0)	166 (66.7)
Don't know	68 (19.1)	19 (17.8)	49 (19.7)
Correct immunization schedule			
Yes	214 (60.1)	70 (65.4)	144 (57.8)
No	33 (9.3)	5 (4.7)	28 (11.2)
Don't know	109 (30.6)	32 (29.9)	77 (30.9)
History of needle stick injuries			
Yes	26 (7.3)	5 (4.7)	21 (8.4)
No	330 (92.7)	102 (95.3)	228 (91.6)

Abbreviations: Anti-HBs, hepatitis B surface antibody; BMI, Body Mass Index.

^a Values are expressed as mean ± standard deviation or number (%).^b < 10 mIU/mL.^c ≥ 10 mIU/mL.

levels (≥ 10 mIU/mL), while 107 participants (30.1%) exhibited insufficient levels (< 10 mIU/mL). No significant differences were observed between these two groups regarding the study variables (Figure 2).

Among those with sufficient antibody levels (≥ 10 mIU/mL), participants were further categorized into two

subgroups based on their anti-HBs levels. The first subgroup included 187 participants (75.1%) with 10 mIU/mL < anti-HBs < 100 mIU/mL, while the second subgroup comprised 62 individuals (24.9%) with anti-HBs levels ≥ 100 mIU/mL. Comparative analysis between




Figure 2. Baseline variables comparison between groups with insufficient and sufficient Hepatitis B surface antibody (Anti-HBs) levels. Insufficient Anti-HBs: < 10 mIU/mL; Sufficient Anti-HBs: ≥ 10 mIU/mL; ns: Not significant.

these subgroups revealed no significant differences in their characteristics (Table 2).

4.2. After Vaccination

Participants with insufficient antibody levels (< 10 mIU/mL) received a booster dose of the hepatitis B vaccine. Of the 107 individuals, 11 participants did not return for a follow-up anti-HBs test. Among the remaining 96 participants, 93 (96.9%) achieved sufficient antibody levels after vaccination (≥ 10 mIU/mL), while three individuals (3.1%) continued to exhibit insufficient levels (< 10 mIU/mL). Analysis revealed no significant differences in demographic or baseline characteristics between these two groups.

The group with sufficient anti-HBs levels after vaccination was further divided into two subgroups: Twenty participants (24.9%) with 10 mIU/mL < anti-HBs < 100 mIU/mL and 73 participants (75.1%) with anti-HBs ≥ 100 mIU/mL. No significant differences were observed between these two subgroups regarding the study variables.

5. Discussion

This study assessed anti-HBs levels among health sciences students to evaluate HBV immunity and the effect of a booster dose on individuals with insufficient antibody levels. Among the 356 participants, 69.9% (249 individuals) demonstrated sufficient antibody levels (≥ 10 mIU/mL), with 75.1% in the range of 10 mIU/mL < anti-HBs < 100 mIU/mL and 24.9% having anti-HBs ≥ 100 mIU/mL. Meanwhile, 30.1% (107 individuals) exhibited inadequate antibody levels (< 10 mIU/mL). Participants with insufficient antibody levels received a hepatitis B vaccine booster. Of the 107 individuals, 96 underwent follow-up testing, where 93 (96.9%) achieved sufficient levels (≥ 10 mIU/mL), while three (3.1%) remained with inadequate levels (< 10 mIU/mL).

Nearly all participants in this study reported receiving HBV vaccination during infancy, consistent with previous studies in Iran (16). This high vaccination rate is largely due to a nationwide public health initiative launched in 1993, which provides vaccination to nearly all neonates (17). Enrollment in schools in Iran

Table 2. Demographic Differences Across Various Hepatitis B Surface Antibody Levels Within the Group with Sufficient Hepatitis B Surface Antibody Levels ^a

Variables	10 mIU/mL < Anti-HBs < 100 mIU/mL (N = 187)	100 mIU/mL ≤ Anti-HBs (N = 62)	P-Value
Age (y)	21.6 ± 1.8	21.4 ± 1.8	0.516
Gender			0.192
Male	149 (79.7)	54 (87.1)	
Female	38 (20.3)	8 (12.9)	
Field of study			0.319
Medicine	87 (46.5)	27 (43.5)	
Nursing	60 (32.1)	20 (32.3)	
Para medicine	34 (18.2)	11 (17.7)	
Dentistry	6 (3.2)	4 (6.4)	
Year of study			0.463
First	65 (34.8)	26 (41.9)	
Second	56 (29.9)	20 (32.3)	
Third	40 (21.4)	8 (12.9)	
Fourth and above	26 (13.9)	8 (12.9)	
Weight (kg)	72.7 ± 12.7	74.1 ± 14.0	0.469
Height (cm)	175.6 ± 9.2	178.3 ± 8.8	0.053
BMI (kg/m²)	23.5 ± 3.1	23.3 ± 4.0	0.707
BMI category			0.486
Underweight	6 (3.2)	4 (6.5)	
Normal	130 (69.5)	40 (64.5)	
Overweight and obese	51 (27.3)	18 (29.0)	
Infancy vaccination			0.213
Yes	178 (95.2)	62 (100)	
No	0 (0)	0 (0)	
Don't know	9 (4.8)	0 (0)	
Number of doses in infancy			0.332
One	3 (1.6)	3 (4.8)	
Two	22 (11.8)	6 (9.7)	
Three	128 (68.4)	38 (61.3)	
Don't know	34 (18.2)	15 (24.2)	
Correct immunization schedule			0.169
Yes	110 (58.8)	34 (54.8)	
No	17 (9.1)	11 (17.7)	
Don't know	60 (32.1)	17 (27.4)	
History of needle stick injuries			0.901
Yes	16 (8.6)	5 (8.1)	
No	171 (91.4)	57 (91.9)	

Abbreviations: Anti-HBs, hepatitis B surface antibody; BMI, Body Mass Index.

^a Values are expressed as mean ± standard deviation or number (%).

requires proof of vaccination. Therefore, even participants uncertain of their vaccination status were likely vaccinated.

However, hepatitis B vaccination rates vary considerably across different regions. For instance, in Cameroon, only about 11% of HCWs were fully vaccinated against HBV (18), while in Brazil, 48.9% of medical students had received the hepatitis B vaccine (19). Similarly, in the Kurdistan Region of Iraq, half of the

medical sciences students were unvaccinated (20). In contrast, Europe has a higher prevalence of complete HBV vaccination among HCWs, ranging from 85% to 100% (16). These discrepancies highlight the varying levels of vulnerability among health sciences students and HCWs globally, emphasizing the critical need for enhanced vaccination initiatives in under-vaccinated regions.

In the current study, 69.9% of participants had adequate anti-HBs titers. Prior studies on health sciences students and HCWs reported varying prevalence rates of sufficient anti-HBs levels. Similar to our findings, Batra et al. observed that among vaccinated HCWs in India, 30% had anti-HBs < 10 mIU/mL, while 70% had sufficient anti-HBs levels (10.8% between 10 - 100 mIU/mL and 59.2% > 100 mIU/mL) (2). Hiva et al. reported that 83% of HCWs in Iran were serologically immune to HBV infection (16). Sukriti et al. found that 61.7% of HCWs in an Indian tertiary care hospital had protective (> 10 IU/mL) anti-HBs levels (21).

Nevertheless, some studies reported lower prevalence rates of HBV immunity among HCWs and health sciences students. For example, Mirambo et al., in a cross-sectional study in Tanzania, found that only 22% of health professional students had sufficient anti-HBs (≥ 10 IU/L). Among these, 69.4% had levels between 10 and 100 IU/L, and 30.6% had levels higher than 100 IU/L. However, these students had not received the hepatitis B vaccine during infancy (12). Similarly, Phattraprayoon et al. investigated long-term immunity among medical students and HCWs in Thailand vaccinated against HBV during infancy and reported a 49% prevalence of protective immunity (anti-HBs ≥ 10 mIU/mL) (5). These differences likely reflect variations in national vaccination programs and protocols across regions. Additionally, anti-HBs levels naturally decline over time after vaccination (22, 23), meaning differences in participants' ages and the interval between vaccination and antibody assessment may explain some of the observed disparities.

Despite these differences, a consistent finding across studies is that a considerable proportion of health sciences students or HCWs demonstrate insufficient anti-HBs levels. Immunity acquired through vaccination during infancy may not provide lifelong protection against HBV (5). Previous research shows that anti-HBs levels decline with time following vaccination (22, 23). Studies have demonstrated that individuals vaccinated more than ten years ago tend to have lower anti-HBs titers compared to those vaccinated within the past five years (21). For instance, a study of medical students and HCWs found that 20% and 27% lacked protection 5 and 10 years after vaccination, respectively (22). Current evidence underscores the importance of conducting antibody tests post-vaccination, particularly for HCWs, to confirm established immunity against HBV (16).

The decision to administer a booster hepatitis B vaccine to individuals with insufficient anti-HBs levels despite completing the full vaccination regimen remains a complex issue. There is ongoing debate

regarding the benefits of a booster dose for HCWs with inadequate antibody levels. While some researchers argue against the need for booster doses, others advocate for them, particularly for individuals at ongoing risk of exposure (5, 7-11, 24, 25). Some studies even recommend mandatory booster doses for healthcare professionals (22). However, many studies supporting booster doses lack prolonged follow-up periods for participants.

In this study, participants with insufficient anti-HBs levels received a booster dose, resulting in 96.9% achieving adequate antibody levels. These findings align with those of Costa et al., who reported a 95% response rate to a booster dose in individuals with inadequate antibody levels (25). Similarly, Hiva et al. documented that 91% of participants with initially insufficient anti-HBs levels reached sufficient levels following a booster dose (16). Bruce et al. observed an 88% response rate to a booster dose among participants with anti-HBs levels below 10 mIU/mL (9).

Prior studies have demonstrated that declining anti-HBs levels may increase infection risk, as reduced neutralizing antibodies might be insufficient to prevent HBV infection (26). Consequently, a booster dose could benefit individuals at high risk who exhibit inadequate antibody levels. However, other studies suggest that initial vaccination provides adequate protection even in the absence of detectable anti-HBs levels, with evidence of persistent immunological memory (25, 27). Moreover, long-lasting cellular immunity conferred by vaccination may provide protection independent of anti-HBs titers (28).

Further research is necessary to clarify the necessity and efficacy of a booster dose in health sciences students and HCWs with insufficient anti-HBs titers, particularly to balance the risks and benefits in this high-risk population.

5.1. Strengths and Limitations

This study addressed an important public health concern for health sciences students, who face a heightened risk of hepatitis B infection due to occupational exposure. It took a comprehensive approach by assessing immunity status, measuring anti-HBs titers, and evaluating the impact of booster doses on participants with insufficient antibody levels. Efforts were made to ensure diversity by including students from various fields and entry years, providing a broader perspective on HBV immunity among this high-risk population.

However, the study had certain limitations. Conducting the research at a single center may limit the

generalizability of the findings to HCWs or students in different regions or institutional settings. Additionally, some data were self-reported, which may introduce recall bias. The characteristics of participants who opted to participate might differ from those who declined, potentially affecting the representativeness of the sample. Furthermore, other potential risk factors contributing to low antibody levels, which were not included in the analysis, may also exist. Lastly, the short follow-up period after the booster dose may not fully capture the long-term effects and stability of antibody levels, which warrants further investigation in future studies.

5.2. Conclusions

In this study, 30% of health sciences students demonstrated inadequate (< 10 mIU/mL) anti-HBs titers. The administration of a booster dose significantly improved immunity, with 96.9% of participants achieving sufficient (≥ 10 mIU/mL) anti-HBs levels. These findings can inform the development of a protocol for HBV vaccination among students at Aja University of Medical Sciences upon their enrollment. Further research with larger sample sizes and extended follow-up periods is recommended to better assess anti-HBs titers and the long-term effects of booster doses in populations at high risk for hepatitis B.

Footnotes

Authors' Contribution: Study concept and design: S. J. H. Sh.; Acquisition of data: M. B. and M. Gh.; Analysis and interpretation of data: S. J. H. Sh.; Drafting of the manuscript: S. J. H. Sh. and A. F.; Critical revision of the manuscript for important intellectual content: I. N.; Statistical analysis: S. J. H. Sh.; Administrative, technical, and material support: M. Gh. and M. B.; Study supervision: S. J. H. Sh. and I. N.

Conflict of Interests Statement: The authors declare that they have no conflict of interests.

Data Availability: The dataset presented in the study is available on request from the corresponding author during submission or after publication. The data are not publicly available due to privacy or ethical restrictions.

Ethical Approval: The Research Ethics Committees of Aja University of Medical Sciences approved this study (Approval number: IR.AJAUMS.REC.1401.156).

Funding/Support: The authors did not receive support from any organization for the submitted work.

Informed Consent: Informed consent was obtained from participants before enrollment.

References

1. US Public Health Service. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. *MMWR Recomm Rep*. 2001;**50**(RR-11):1-52. [PubMed ID: [11442229](#)].
2. Batra V, Goswami A, Dadhich S, Kothari D, Bhargava N. Hepatitis B immunization in healthcare workers. *Ann Gastroenterol*. 2015;**28**(2):276-80. [PubMed ID: [25830669](#)]. [PubMed Central ID: [PMC4367220](#)].
3. Ristinen E, Mamtani R. Ethics of transmission of hepatitis B virus by health-care workers. *Lancet*. 1998;**352**(9137):1381-3. [PubMed ID: [9802291](#)]. [https://doi.org/10.1016/S0140-6736\(98\)03095-5](https://doi.org/10.1016/S0140-6736(98)03095-5).
4. Roggendorf M, Viazov S. Health care workers and hepatitis B. *J Hepatol*. 2003;**39** Suppl 1:S89-92. [PubMed ID: [14708684](#)]. [https://doi.org/10.1016/S0168-8278\(03\)00313-1](https://doi.org/10.1016/S0168-8278(03)00313-1).
5. Phattraprayoon N, Kakheaw J, Soonklang K, Cheirsilpa K, Ungtrakul T, Auewarakul C, et al. Duration of Hepatitis B Vaccine-Induced Protection among Medical Students and Healthcare Workers following Primary Vaccination in Infancy and Rate of Immunity Decline. *Vaccines (Basel)*. 2022;**10**(2). [PubMed ID: [35214725](#)]. [PubMed Central ID: [PMC8878162](#)]. <https://doi.org/10.3390/vaccines10020267>.
6. Van Damme P. Long-term Protection After Hepatitis B Vaccine. *J Infect Dis*. 2016;**214**(1):1-3. [PubMed ID: [26802140](#)]. <https://doi.org/10.1093/infdis/jiv750>.
7. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Crasta PD, Messier M, Hardt K. Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: a 20-year follow-up study in Thailand. *Hum Vaccin Immunother*. 2013;**9**(8):1679-84. [PubMed ID: [23732904](#)]. [PubMed Central ID: [PMC3906265](#)]. <https://doi.org/10.4161/hv.24844>.
8. Ma JC, Wu ZW, Zhou HS, Gao Z, Hao ZY, Jin F, et al. Long-term protection at 20-31 years after primary vaccination with plasma-derived hepatitis B vaccine in a Chinese rural community. *Hum Vaccin Immunother*. 2020;**16**(1):16-20. [PubMed ID: [31339432](#)]. [PubMed Central ID: [PMC7012072](#)]. <https://doi.org/10.1080/21645515.2019.1646575>.
9. Bruce MG, Bruden D, Hurlburt D, Zanis C, Thompson G, Rea L, et al. Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose. *J Infect Dis*. 2016;**214**(1):16-22. [PubMed ID: [26802139](#)]. <https://doi.org/10.1093/infdis/jiv748>.
10. Klinger G, Chodick G, Levy I. Long-term immunity to hepatitis B following vaccination in infancy: Real-world data analysis. *Vaccin J*. 2018;**36**(17):2288-92. [PubMed ID: [29573878](#)]. <https://doi.org/10.1016/j.vaccine.2018.03.028>.
11. Pileggi C, Papadopolis R, Bianco A, Pavia M. Hepatitis B vaccine and the need for a booster dose after primary vaccination. *Vaccin J*. 2017;**35**(46):6302-7. [PubMed ID: [28988867](#)]. <https://doi.org/10.1016/j.vaccine.2017.09.076>.
12. Mirambo MM, Mkumbo E, Selega H, Msemwa B, Mushi MF, Silago V, et al. Hepatitis B virus infections among health professional students in Mwanza city, Tanzania in 2016. *Arch Public Health*. 2020;**78**:76. [PubMed ID: [32832080](#)]. [PubMed Central ID: [PMC7436995](#)]. <https://doi.org/10.1186/s13690-020-00459-2>.
13. Charan J, Biswas T. How to calculate sample size for different study designs in medical research? *Indian J Psychol Med*. 2013;**35**(2):121-6. [PubMed ID: [24049221](#)]. [PubMed Central ID: [PMC3775042](#)]. <https://doi.org/10.4103/0253-7176.116232>.

14. Centers for Disease Control and Prevention. *Child and Adolescent Immunization Schedule*. 2024. Available from: <https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent.html>.
15. Weir CB, Jan A. BMI Classification Percentile And Cut Off Points. *StatPearls*. Treasure Island (FL); 2024. eng.
16. Hiva S, Negar K, Mohammad-Reza P, Gholam-Reza G, Mohsen A, Ali-Asghar NG, et al. High level of vaccination and protection against hepatitis B with low rate of HCV infection markers among hospital health care personnel in north of Iran: a cross-sectional study. *BMC Public Health*. 2020;**20**(1):920. [PubMed ID: 32532228]. [PubMed Central ID: PMC7291184]. <https://doi.org/10.1186/s12889-020-09032-6>.
17. Mohammadi Z, Keshkar A, Eghtesad S, Jeddian A, Pourfatholah AA, Maghsudlu M, et al. Epidemiological Profile of Hepatitis B Virus Infection in Iran in the Past 25 years; A Systematic Review and Meta-analysis of General Population Studies. *Middle East J Dig Dis*. 2016;**8**(1):5-18. [PubMed ID: 26933476]. [PubMed Central ID: PMC4773083]. <https://doi.org/10.1517/mejdd.2016.01>.
18. Bilounga Ndongo C, Eteki L, Siedner M, Mbaye R, Chen J, Ntone R, et al. Prevalence and vaccination coverage of Hepatitis B among healthcare workers in Cameroon: A national seroprevalence survey. *J Viral Hepat*. 2018;**25**(12):1582-7. [PubMed ID: 30047565]. [PubMed Central ID: PMC6717319]. <https://doi.org/10.1111/jvh.12974>.
19. Souza EP, Teixeira Mde S. Hepatitis B vaccination coverage and postvaccination serologic testing among medical students at a public university in Brazil. *Rev Inst Med Trop Sao Paulo*. 2014;**56**(4):307-11. [PubMed ID: 25076431]. [PubMed Central ID: PMC4131816]. <https://doi.org/10.1590/s0036-46652014000400007>.
20. Naqid IA, Mosa AA, Ibrahim SV, Ibrahim NH, Hussein NR. Hepatitis B vaccination status and knowledge, attitude, and practice towards Hepatitis B virus among medical sciences students: A cross-sectional study. *PLoS One*. 2023;**18**(11). e0293822. [PubMed ID: 37930973]. [PubMed Central ID: PMC10627443]. <https://doi.org/10.1371/journal.pone.0293822>.
21. Pati NT, Sethi A, Agrawal K, Agrawal K, Kumar GT, Sukriti, et al. Low levels of awareness, vaccine coverage, and the need for boosters among health care workers in tertiary care hospitals in India. *J Gastroenterol Hepatol*. 2008;**23**(11):1710-5. [PubMed ID: 18761556]. <https://doi.org/10.1111/j.1440-1746.2008.05483.x>.
22. Sahana HV, Sarala N, Prasad SR. Decrease in Anti-HBs Antibodies over Time in Medical Students and Healthcare Workers after Hepatitis B Vaccination. *Biomed Res Int*. 2017;**2017**:1327492. [PubMed ID: 29082237]. [PubMed Central ID: PMC5634573]. <https://doi.org/10.1155/2017/1327492>.
23. Lee KH, Shim KS, Lim IS, Chae SA, Yun SW, Lee NM, et al. Changes in hepatitis B virus antibody titers over time among children: a single center study from 2012 to 2015 in an urban of South Korea. *BMC Pediatr*. 2017;**17**(1):164. [PubMed ID: 28705230]. [PubMed Central ID: PMC5512724]. <https://doi.org/10.1186/s12887-017-0924-7>.
24. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? *The Lancet*. 2000;**355**(9203):561-5. [https://doi.org/10.1016/s0140-6736\(99\)07239-6](https://doi.org/10.1016/s0140-6736(99)07239-6).
25. Costa M, Durlach R, Laugas S, Freuler CB, Rodriguez VE. Ten-year persistence of antibody to hepatitis B surface antigen in healthcare workers vaccinated against hepatitis B virus, and response to booster vaccination. *Infect Control Hosp Epidemiol*. 2003;**24**(10):773-6. [PubMed ID: 14587943]. <https://doi.org/10.1086/502132>.
26. Stramer SL, Wend U, Candotti D, Foster GA, Hollinger FB, Dodd RY, et al. Nucleic acid testing to detect HBV infection in blood donors. *N Engl J Med*. 2011;**364**(3):236-47. [PubMed ID: 21247314]. <https://doi.org/10.1056/NEJMoa1007644>.
27. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. *Ann Intern Med*. 2001;**135**(9):796-800. [PubMed ID: 11694104]. <https://doi.org/10.7326/0003-4819-135-9-20011060-00009>.
28. Simons BC, Spradling PR, Bruden DJ, Zanis C, Case S, Choromanski TL, et al. A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen. *J Infect Dis*. 2016;**214**(2):273-80. [PubMed ID: 27056956]. [PubMed Central ID: PMC4918827]. <https://doi.org/10.1093/infdis/jiw142>.